Early detection is critical in providing curative therapies for the vast majority of solid malignancies. Recent data from our own group and others suggest that circulating tumor cells (CTCs) may be shed in significant numbers into the blood stream of patients with invasive but localized cancers. Dissemination of abnormal cells has even been reported in patients with preneoplastic breast lesions (DCIS). Together, these observations suggest that, rather than being rare and late events in the evolution of cancer, the presence of CTCs may be an early herald of tumor vascular invasion, preceding a considerable period of time for the eventual establishment of viable distant metastases. This concept provides a radical departure from current approaches to early cancer detection, which are based on either radiographic screening or the development of reliable serum proteomic approaches. Testing for the presence of bona fide CTCs in the circulation would constitute a very powerful tool for early detection of cancer, but also requires the development of highly sensitive and reliable technology. The current approaches to microfluidic CTC detection that we have developed have sufficient capability to detect the presence of CTCs in some patients with early cancers, but they need to be greatly enhanced in both sensitivity and throughput to become valid for eventual application to population screening. Here, we propose technological innovations to allow such sensitive and robust CTC detection strategies, making use of enhanced microfluidic isolation and capture (Aim 1), as well as molecular tools for quantitation of minimal CTC numbers (Aim 2). Human studies will be given priority and will provide a rigorous test of our technological innovations and biological discoveries. This is a philosophical decision in that the project investigators strongly believe that to achieve the Quantum Project vision of "solving or profoundly improving a specific health condition using technology-driven approaches" in a time period of 5 years, the project must have a sharp focus on "real" systems at the onset of the program We propose a graded clinical application of these developing technologies, first in patients with known localized lung or breast cancer, and then in patients with newly diagnosed suspicious radiographic lesions that have been selected for biopsy (Aim 3). If successful, the combined bioengineering and molecular approaches proposed here would lead to indications for large scale screening studies in patients with environmental or genetic susceptibility to lung or breast cancers. Together, we have established a multidisciplinary team of researchers focused on extending CTC detection technologies to the challenge of early detection of invasive but localized cancers, with the potential for revolutionary approaches to cancer prevention.

Public Health Relevance

The next major hurdle in the management and treatment of cancer patients is early detection. The proposed point-of-care microchip to non-invasively isolate circulating tumor cells from the peripheral blood of cancer patients and ultimately general population for early detection has the potential to revolutionize the management of cancer patients with concomitant increase in survival rates.

National Institute of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZEB1-OSR-E (A1))
Program Officer
Korte, Brenda
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Luo, Xi; Mitra, Devarati; Sullivan, Ryan J et al. (2014) Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7:645-53
Sullivan, James P; Nahed, Brian V; Madden, Marissa W et al. (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-309
Aceto, Nicola; Bardia, Aditya; Miyamoto, David T et al. (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110-22
Yu, Min; Bardia, Aditya; Aceto, Nicola et al. (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345:216-20
Karabacak, Nezihi Murat; Spuhler, Philipp S; Fachin, Fabio et al. (2014) Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9:694-710
Ozkumur, Emre; Shah, Ajay M; Ciciliano, Jordan C et al. (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47
Shah, Ajay M; Yu, Min; Nakamura, Zev et al. (2012) Biopolymer system for cell recovery from microfluidic cell capture devices. Anal Chem 84:3682-8